Yakult Honsha Co.,Ltd. (2267.T) Stock

About Yakult Honsha Co.,Ltd.

Yakult Honsha Co.,Ltd. is a diversified Japanese enterprise engaged in the manufacturing and sale of a broad array of products, including food and beverages, cosmetics, and pharmaceuticals. The company's operations are segmented geographically for its Food and Beverages division, covering Japan, the Americas, Asia and Oceania, and Europe, alongside dedicated Pharmaceutical and "Others" segments. Its extensive food and beverage offerings feature popular items such as fermented milk beverages, various juices, and noodle products, which are distributed through both a home delivery service and traditional retail channels. In the pharmaceutical sector, Yakult Honsha provides specific medications like the antineoplastic drug Elplat, along with a suite of generic anti-cancer treatments, including Gemcitabine Yakult, Capecitabine, and Gefitinib Yakult tablets. Furthermore, the company maintains a presence in the cosmetics industry and is notably the owner of the professional baseball team, the Tokyo Yakult Swallows. Founded in 1935, Yakult Honsha Co.,Ltd. is headquartered in Tokyo, Japan.

Yakult Honsha Co.,Ltd. is led by CEO Hiroshi Natsume, employs 29,618 people, headquartered in Tokyo, JP, publicly traded since 2001.

over the past 52 weeks the stock has ranged between $2291.00 and $3092.00, and currently trades 6.7% below its 52-week high.

Official website: www.yakult.co.jp